Blog

Olivia Mannix is Dedicated to Female-Focused Medicines – Podcast Episode #25

Apr 5 • 1 min read

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Olivia Mannix. Olivia is an award-winning entrepreneur and cannabis & psychedelics business pioneer. Olivia is the intuitive leader of marketing and the business revolution. She founded one of the first ancillary cannabis companies, Cannabrand in 2013. Being the innovator behind the…

MindMed – Bullish vs Bearish: Episode #8

Apr 4 • 1 min read

In this episode of Bullish vs Bearish, Adam Tubero talks about Mind Medicine ($MNMD). Are you Bullish or Bearish? Watch the video and leave a comment. As always, you can like, comment, and share the video directly from Youtube.

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

Apr 4 • 3 min read

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the pricing of its United States only public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to…

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Apr 4 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”). AGN Neuro…

First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health

Apr 4 • 2 min read

Diamond Therapeutics Inc., a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce a strategic investment round led by First Avenue Ventures Life Science Fund I (FAV LS Fund I), a multimillion-dollar life science fund with a focus on supporting research developed at the University…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538